# Table of Contents

HEADER .......................................................... 1
ABSTRACT ........................................................ 1
PLAIN LANGUAGE SUMMARY ..................................... 2
BACKGROUND ....................................................... 2
OBJECTIVES ....................................................... 2
METHODS .......................................................... 3
RESULTS ........................................................... 3
  Figure 1 ......................................................... 5
  Figure 2 ......................................................... 6
DISCUSSION ....................................................... 6
AUTHORS’ CONCLUSIONS ........................................ 6
REFERENCES ........................................................ 7
CHARACTERISTICS OF STUDIES ............................... 8
DATA AND ANALYSES ............................................ 14
  Analysis 1.1. Comparison 1 ICP-directed mannitol (‘treatment’) compared to mannitol according to neurological signs ('control'), Outcome 1 Death. .......................................................... 15
  Analysis 1.2. Comparison 1 ICP-directed mannitol (‘treatment’) compared to mannitol according to neurological signs ('control'), Outcome 2 Death or severe disability. .............................................. 15
  Analysis 2.1. Comparison 2 Mannitol versus pentobarbital, Outcome 1 Death. .................................................. 16
  Analysis 3.1. Comparison 3 Mannitol versus hypertonic saline, Outcome 1 Death. .................................................. 16
  Analysis 4.1. Comparison 4 Mannitol versus placebo, Outcome 1 Death. .................................................. 17
APPENDICES ....................................................... 17
FEEDBACK ........................................................ 19
WHAT’S NEW ..................................................... 20
HISTORY .......................................................... 20
CONTRIBUTIONS OF AUTHORS .............................. 21
DECLARATIONS OF INTEREST ............................... 21
SOURCES OF SUPPORT ........................................... 21
INDEX TERMS ...................................................... 21
Mannitol for acute traumatic brain injury

Abel Wakai1, Aileen McCabe1, Ian Roberts2, Gillian Schierhout3

1Emergency Care Research Unit (ECRU), Division of Population Health Sciences (PHS), Royal College of Surgeons in Ireland, Dublin 2, Ireland. 2Cochrane Injuries Group, London School of Hygiene & Tropical Medicine, London, UK. 3c/o Cochrane Injuries Group, London School of Hygiene & Tropical Medicine, London, UK

Contact address: Abel Wakai, Emergency Care Research Unit (ECRU), Division of Population Health Sciences (PHS), Royal College of Surgeons in Ireland, 123 St. Stephen’s Green, Dublin 2, Ireland. awakai@rcsi.ie. abelwakai@gmail.com.

Editorial group: Cochrane Injuries Group.
Publication status and date: Edited (no change to conclusions), published in Issue 8, 2013.
Review content assessed as up-to-date: 20 April 2009.


Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Mannitol is sometimes effective in reversing acute brain swelling, but its effectiveness in the ongoing management of severe head injury remains unclear. There is evidence that, in prolonged dosage, mannitol may pass from the blood into the brain, where it might cause increased intracranial pressure.

Objectives

To assess the effects of different mannitol therapy regimens, of mannitol compared to other intracranial pressure (ICP) lowering agents, and to quantify the effectiveness of mannitol administration given at other stages following acute traumatic brain injury.

Search methods

We searched the Cochrane Injuries Group Specialised Register, CENTRAL (The Cochrane Library), MEDLINE (OvidSP), EMBASE (OvidSP), ISI Web of Science (SCI-EXPANDED & CPCI-S) and PubMed. We checked reference lists of trials and review articles, and contacted authors of trials. The search was updated on the 20th April 2009.

Selection criteria

Randomised controlled trials of mannitol, in patients with acute traumatic brain injury of any severity. The comparison group could be placebo-controlled, no drug, different dose, or different drug. We excluded cross-over trials, and trials where the intervention was started more than eight weeks after injury.

Data collection and analysis

We independently rated quality of allocation concealment and extracted the data. Relative risks (RR) and 95% confidence intervals (CI) were calculated for each trial on an intention to treat basis.

Main results

We identified four eligible randomised controlled trials. One trial compared ICP-directed therapy to ‘standard care’ (RR for death = 0.83; 95% CI 0.47 to 1.46). One trial compared mannitol to pentobarbital (RR for death = 0.85; 95% CI 0.52 to 1.38). One trial compared mannitol to hypertonic saline (RR for death = 1.25; 95% CI 0.47 to 3.33). One trial tested the effectiveness of pre-hospital administration of mannitol against placebo (RR for death = 1.75; 95% CI 0.48 to 6.38).
Authors’ conclusions

Mannitol therapy for raised ICP may have a beneficial effect on mortality when compared to pentobarbital treatment, but may have a detrimental effect on mortality when compared to hypertonic saline. ICP-directed treatment shows a small beneficial effect compared to treatment directed by neurological signs and physiological indicators. There are insufficient data on the effectiveness of pre-hospital administration of mannitol.
Criteria for considering studies for this review

Types of studies
Controlled trials in which subjects were assigned to treatment or control groups (placebo-controlled, no drug, different drug or different mannitol regimen) on the basis of random or quasi-random allocation. We excluded trials with a cross-over design.

Types of participants
Participants had a clinically defined acute traumatic brain injury of any severity.

Types of interventions
The treatment group received mannitol in any dose for any duration, at any time within eight weeks following injury. The control group received any of the following: mannitol in a different dose from the treatment group, another ICP-lowering agent such as barbiturates or placebo or standard care only.

Types of outcome measures
We aimed to extract from each trial the number of patients originally allocated to each group. Within each group, we aimed to extract the number of participants who died from any cause during the follow-up period or who were dead, in a vegetative state or severely disabled, compared to moderate or good recovery (according to Glasgow Coma Scale [GCS] criteria).

Search methods for identification of studies
The search was limited by date, language or publication type.

Electronic searches
The Cochrane Injuries Group Trials Search Co-ordinator searched the following:
1. Cochrane Injuries Group Specialised Register (20th April 2009);
2. CENTRAL (The Cochrane Library 2009, Issue 2);
3. MEDLINE (OvidSP) (1950 to April 2009);
4. EMBASE (OvidSP) (1980 to April 2009);
5. ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) 1970 to April 2009;
6. Conference Proceedings Citation Index- Science (CPCI-S) 1990 to April 2009;
7. PubMed (added in last 6 months; searched 21 April 2009).
Search strategies are listed in Appendix 1.

Data collection and analysis
We determined eligibility by reading the reports of possible trials and corresponding with the trialists. The reviewers independently rated quality of allocation concealment and independently extracted the data. We resolved disagreement by discussion. We calculated relative risks and 95% confidence intervals for each trial on an intention to treat basis. For trials which used comparable treatment regimens, we planned to calculate summary relative risks and 95% confidence intervals using a fixed effects model, and to stratify the analyses on allocation concealment.

Results
Description of studies
Four studies met the inclusion criteria.
Sayre 1996 compared the pre-hospital administration of mannitol with placebo (normal saline). Eligible patients were those with moderate and severe head injury (GCS 11 or less), above 18 years of age. Patients were excluded if they may have been pregnant, had already received a diuretic, or were receiving cardiopulmonary resuscitation. The mannitol group received 5ml/kg of 20% mannitol through a large bore IV catheter over five minutes. The placebo group was given 5ml/kg of 0.9% saline solution. Forty-four participants were randomised; three were later excluded as they were found to be ineligible. The treatment to which these three patients were allocated, as well as follow-up information were unavailable. Therefore, the analysis was based upon 20 participants in the mannitol group and 21 participants in the placebo group. Length of follow-up was for two hours after arrival at the hospital.
Schwartz 1984 compared mannitol to pentobarbital. Patients with severe head injury (GCS <8), and with raised ICP for longer than 15 minutes were eligible. Treatment allocation was stratified according to the presence of intracranial haematomas. The mannitol group received 20% mannitol solution at an initial dose of 1g per kg. Additional increments were given to maintain the intracranial
pressure at less than 20 torr, within a serum osmolality of mannitol of 320mOs/litre. The pentobarbital group received pentobarbital as an intravenous (IV) bolus of up to 10mg/kg, followed by a continuous infusion at 0.5 to 3mg/kg/hr, provided that CPP remained above 50 torr. Additional increments of pentobarbital were given to maintain the intracranial pressure at less than 20 torr. For subsequent episodes of raised ICP, there was some cross-over to the alternate treatment group, but the analysis was on the original intent-to-treat. Seventy participants were randomised; 11 were later deemed ineligible and excluded. Data on the treatment to which these 11 patients were allocated and follow-up information were unavailable. Therefore, the analysis was based on 31 participants in the mannitol group and 28 participants in the pentobarbital group. Length of follow-up was one year.

Smith 1986 compared two regimens for guiding the administration of mannitol, one according to neurological signs and physiological measurements, and the other using ICP monitoring. Participants had a severe head injury (GCS 8 or less). The protocol for the first group used neurological signs, GCS, ventilatory values and arterial blood gas to guide administration of mannitol. In the second group, a 250ml bolus of mannitol (20%) was given if ICP > 25mmHg, and subsequent boluses were given incrementally. Eighty participants were randomised. Data were available for 40 participants in the first group, and 37 participants in the ICP-directed treatment group. Follow-up was one year.

Vialet 2003 compared mannitol to hypertonic saline. Eligible patients were those with severe head injury (GCS <8) who required intravenous infusions of an osmotic agent to treat episodes of intracranial hypertension resistant to standard therapy (cerebrospinal fluid drainage, volume expansion and/or inotropic support, hyperventilation). The mannitol group received 20% mannitol solution. The hypertonic saline group received 7.5% hypertonic saline. The infused volume was the same for both solutions: 2 ml/kg body weight in 20 minutes. The aim was to decrease ICP to <25 mm Hg or to increase CPP to >70 mm Hg. In case the first infusion failed, the patient received a second infusion within ten minutes after the end of the first infusion. Treatment failure was defined as the inability to decrease ICP to <35 mm Hg or to increase CPP to >70 mm Hg with two consecutive infusions of the selected osmotic solution. In that case, the protocol was stopped, and patients were followed up for mortality or 90-day neurologic status. Because 20% mannitol can crystallize at ambient temperature, injections could not be performed in a blinded manner. Twenty patients were randomised, ten to each group. Outcome was assessed at 90 days using the Glasgow Outcome Scale administered by a practitioner who was blind to acute patient care.

Risk of bias in included studies

Sayre 1996: The study was randomised and double-blind. Allocation concealment was by pharmacy-prepared blinded solutions.

Schwartz 1984: The study was randomised and single-blind. Allocation concealment was by using serially numbered sealed envelopes.

Smith 1986: The study was randomised but not reported as double-blind. Allocation concealment was by the use of sealed envelopes.

Vialet 2003: The study was randomised but allocation concealment was not described. Outcome assessment was blind to acute clinical care.

The risk of bias across the four studies is summarised in Figure 1 and Figure 2.
Figure 1. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
**Effects of interventions**

One trial compared ICP-directed therapy to ‘standard care’ in which mannitol therapy was directed by neurological signs (Smith 1986). The study was randomised and allocation concealment was by the use of sealed envelopes. For ICP-directed treatment compared to treatment based on neurological signs, the RR for death was 0.83 (95% CI 0.47 to 1.46); this trial demonstrated a similar effect for death or severe disability (RR = 0.88; 95% CI 0.55 to 1.38).

One trial compared mannitol to pentobarbital (Schwartz 1984). This trial was randomised and single blind. Only patients with known raised ICP were included. For mannitol compared to pentobarbital in the treatment of patients with raised ICP, the RR for death was 0.85 (95% CI 0.52 to 1.38).

One trial compared mannitol to hypertonic saline (Vialet 2003). This trial was randomised and single blind. Only patients with head injury and persistent coma who required osmotherapy to treat episodes of intracranial hypertension resistant to standard therapy were included. For mannitol compared to hypertonic saline in the treatment of refractory intracranial hypertension episodes in comatose patients with severe head injury, the RR for death was 1.25 (95% CI 0.47 to 3.33).

The effectiveness of pre-hospital administration of mannitol against placebo was investigated in Sayre 1996. This study was randomised and allocation concealment was through pharmacy prepared blinded solutions. For pre-hospital infusion of mannitol compared to placebo in patients with head injury and multiple trauma, the RR for death was 1.75 (95% CI 0.48 to 6.38).

**DISCUSSION**

There were few eligible trials of mannitol therapy in head-injured patients.

ICP-directed treatment showed a small beneficial effect on mortality when compared to treatment directed according to neurological signs and physiological indicators (RR = 0.83; 95% CI 0.47 to 1.46). The method of allocation concealment in this study was adequate to prevent foreknowledge of treatment, and was unlikely to have led to bias. Owing to small patient numbers, the effect measure is imprecise. It must be noted that in this study the ICP-directed protocol initiated mannitol only when the ICP rose to above 25mmHg. Therefore these results cannot be extrapolated to ICP-directed protocols which initiate mannitol therapy at a lower level.

Mannitol therapy may have a beneficial effect on mortality when compared to pentobarbital therapy. However, the single trial which tested this (Schwartz 1984) yielded an imprecise effect measure, which also may be compatible with no difference, or a beneficial effect of pentobarbital. The trial was testing an initial treatment of mannitol compared to pentobarbital as some patients later received the alternate therapy if the allocated therapy failed to control ICP.

Mannitol therapy may have a detrimental effect on mortality when compared to hypertonic saline therapy. The single trial which compared mannitol to hypertonic saline (Vialet 2003) was too small for reliable conclusions. The trial was not designed to test the effect of these osmotic agents on neurologic recovery or death.

The single trial which compared pre-hospital administration of mannitol to placebo showed an increase in mortality amongst the mannitol-treated patients (RR = 1.75; 95% CI 0.48 to 6.38). The estimate yielded by this trial is imprecise owing to the small sample size. The effect measure also may be compatible with no difference, or a beneficial effect of pre-hospital administration of mannitol.

**AUTHORS’ CONCLUSIONS**
Implications for practice

There is insufficient reliable evidence to make recommendations on the use of mannitol in the management of patients with traumatic brain injury.

Implications for research

There are many unanswered questions regarding the optimal use of mannitol following acute traumatic head injury. The widespread current use of mannitol, and lack of clarity regarding optimal administration, present an ideal opportunity for the conduct of randomised controlled trials.

REFERENCES

References to studies included in this review

Sayre 1996  {published data only}

Schwartz 1984  {published data only}

Smith 1986  {published data only}

Vialet 2003  {published data only}

References to studies excluded from this review

Battison 2005  {published data only}

Cruz 2001  {published data only}

Cruz 2002  {published data only}

Cruz 2004  {published data only}

Fortune 1995  {published data only}

Francony 2008  {published data only}

Gaab 1989  {published data only}

Harutjunyan 2005  {published data only}

Ichai 2009  {published data only}

**Levin 1979** *(published data only)*


**Midgely 1993** *(published data only)*


**Smedema 1993** *(published data only)*


**Additional references**

**Ghajar 1995**


**Jeevaratnam 1996**


**Matta 1996**


**Task Force 1995**


* Indicates the major publication for the study
### Characteristics of included studies [ordered by study ID]

**Sayre 1996**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methods</strong></td>
<td>Randomised and double blind placebo controlled trial.</td>
</tr>
<tr>
<td><strong>Participants</strong></td>
<td>Moderate and severe head injury (CGS 11 and less), above 18 years of age</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>Mannitol received 5ml/kg of 20% mannitol through large-bore intravenous catheter over five minutes; placebo group were given 5ml/kg of 0.9% saline solution</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Death was reported. Length of follow-up was two hours after hospital admission</td>
</tr>
<tr>
<td><strong>Notes</strong></td>
<td>Testing pre-hospital administration of mannitol.</td>
</tr>
</tbody>
</table>

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Information not provided in published study.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: “The study solutions were prepared by the pharmacy department and were identified by a code number. An envelope showing the code number identified the contents of that IV bag. If the treating physicians at the receiving trauma center believed it was necessary to know whether the patient had received mannitol or placebo, the envelope could be opened”</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias) All outcomes</td>
<td>Low risk</td>
<td>Comment: Blinding is implied but not explicitly stated. Quote: “This was a prospective, randomized, double-blind, placebo-controlled clinical trial of the effect of mannitol on systolic BP in multiply injured patients with severe head injuries” Quote: “The study solutions were prepared by the pharmacy department and were identified by a code number. An envelope showing the code number identified the contents of that IV bag. If the treating physicians at the receiving trauma center believed it was necessary to know whether the patient had received mannitol or placebo, the envelope could be opened”</td>
</tr>
</tbody>
</table>
Sayre 1996  *(Continued)*

| Quote: “At the conclusion of the 2-hour monitoring period, the EM resident and the investigator recording the patient data were asked to provide their guesses as to whether mannitol or placebo had been administered to the patient. For those patients actually given mannitol, the resident correctly picked mannitol in 11 of 13 cases for which a guess was given; and the investigators correctly picked mannitol in 13 of 14 cases. For those patients actually given placebo, the resident correctly picked placebo in 5 of 10 cases for which a guess was given; and the investigators correctly picked placebo for 13 of 16 cases” |

Schwartz 1984

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised single blind trial.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>Severe head injury (GCS&lt;8). Participants had to have already been resuscitated and had raised ICP for more than 15 minutes</td>
</tr>
<tr>
<td>Interventions</td>
<td>The mannitol group received 20% mannitol solution at an initial dose of 1g per kg. Additional increments were given to maintain the intracranial pressure at less than 20 torr, within a serum osmolarity of mannitol of 320mOs/L. The pentobarbital group received pentobarbital as an IV bolus of up to 10mg/kg, followed by a continuous infusion at 0.5-3 mg/kg/hr, provided that CPP remained above 50 torr. Additional increments of pentobarbital were given to maintain the intracranial pressure at less than 20 torr</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Death reported. Follow-up to three months.</td>
</tr>
<tr>
<td>Notes</td>
<td>For subsequent episodes of raised ICP, cross-over between the groups was allowed</td>
</tr>
</tbody>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “The starting drug was determined by a random number generator.”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: “The mechanism of randomization was the opening of a serially-numbered, sealed envelope taken from one of two packages of envelopes, one for patients who had had intracranial hematomas removed and one for those who developed raised intracranial pressure from brain injury alone.”</td>
</tr>
</tbody>
</table>
### Schwartz 1984 (Continued)

<table>
<thead>
<tr>
<th>Blinding (performance bias and detection bias)</th>
<th>Unclear risk</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Smith 1986

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised controlled trial; not reported as double-blind.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>Severe head injury (GCS 8 or less).</td>
</tr>
<tr>
<td>Interventions</td>
<td>Compared two regimens of guiding the administration of mannitol, one according to neurological signs and physiological measurements, and the other using ICP monitoring. The protocol for the first group used neurological signs, GCS, ventilatory values and arterial blood gas to guide administration. In the second group, a 250ml bolus of mannitol (20%) was given if ICP &gt;25mmHg, and subsequent boluses were given incrementally</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Deaths and neurological disability were reported. Follow-up was one year</td>
</tr>
</tbody>
</table>

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>No information provided in published study.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: “The patients were randomly assigned to one of two groups by means of sealed envelopes containing cards designating the assigned protocol: Group I (mannitol therapy based on ICP monitoring) or Group II (empirical mannitol therapy)”</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias)</td>
<td>Unclear risk</td>
<td>No information provided in published study.</td>
</tr>
</tbody>
</table>

### Vialet 2003

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised single blind trial.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>Severe head injury (GCS&lt;8) who required intravenous infusions of an osmotic agent to treat episodes of intracranial hypertension resistant to standard therapy</td>
</tr>
</tbody>
</table>
### Interventions

Compared two osmotic agents, mannitol and hypertonic saline solution. The mannitol group received 20% mannitol solution. The hypertonic saline group received 7.5% hypertonic saline. The infused volume was the same for both solutions: 2 ml/kg body weight in 20 minutes.

### Outcomes

Death and neurological disability reported. Follow-up to three months.

### Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>No information provided in published study.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: “After randomization, the patients received either 20% mannitol (1160 mOsm/kg/H2O) or 7.5% HSS (2400 mOsm/kg/H2O)”</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias)</td>
<td>High risk</td>
<td>Quote: “Because 20% mannitol can crystallize at ambient temperature, injections could not be performed in a blinded manner.”</td>
</tr>
</tbody>
</table>

### Characteristics of excluded studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Battison 2005</td>
<td>Cross-over design.</td>
</tr>
<tr>
<td>Cruz 2001</td>
<td>Concerns about the integrity of the trial data. Manuscripts does not indicate where the patients were randomised and despite an investigation by the Cochrane Injuries Group this remains open to question</td>
</tr>
<tr>
<td>Cruz 2002</td>
<td>Concerns about the integrity of the trial data. Manuscripts does not indicate where the patients were randomised and despite an investigation by the Cochrane Injuries Group this remains open to question</td>
</tr>
<tr>
<td>Cruz 2004</td>
<td>Concerns about the integrity of the trial data. Manuscripts does not indicate where the patients were randomised and despite an investigation by the Cochrane Injuries Group this remains open to question</td>
</tr>
<tr>
<td>Fortune 1995</td>
<td>Controlled follow up study; no means to reduce bias in the selection of the control group was used</td>
</tr>
<tr>
<td>Francony 2008</td>
<td>Participants were not all head-injured patients.</td>
</tr>
<tr>
<td>Gaab 1989</td>
<td>Randomised to a diuretic, not necessarily mannitol.</td>
</tr>
<tr>
<td>Study</td>
<td>Description</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Harutjunyan 2005</td>
<td>Participants were not all head-injured patients.</td>
</tr>
<tr>
<td>Ichai 2009</td>
<td>Cross-over design.</td>
</tr>
<tr>
<td>Levin 1979</td>
<td>Participants were not all head injured; had a cross-over design</td>
</tr>
<tr>
<td>Midgely 1993</td>
<td>Cross-over design.</td>
</tr>
<tr>
<td>Smedema 1993</td>
<td>Participants were not all head-injured patients.</td>
</tr>
</tbody>
</table>
# Data and Analyses

Comparison 1. ICP-directed mannitol ('treatment') compared to mannitol according to neurological signs ('control')

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Death</td>
<td>1</td>
<td>1</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Subtotals only</td>
</tr>
<tr>
<td>2 Death or severe disability</td>
<td>1</td>
<td>1</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Subtotals only</td>
</tr>
</tbody>
</table>

Comparison 2. Mannitol versus pentobarbital

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Death</td>
<td>1</td>
<td>1</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Subtotals only</td>
</tr>
</tbody>
</table>

Comparison 3. Mannitol versus hypertonic saline

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Death</td>
<td>1</td>
<td>1</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Subtotals only</td>
</tr>
</tbody>
</table>

Comparison 4. Mannitol versus placebo

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Death</td>
<td>1</td>
<td>1</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Subtotals only</td>
</tr>
</tbody>
</table>
### Analysis 1.1. Comparison 1 ICP-directed mannitol ('treatment') compared to mannitol according to neurological signs ('control'), Outcome 1 Death.

**Review:** Mannitol for acute traumatic brain injury

**Comparison:** 1 ICP-directed mannitol ('treatment') compared to mannitol according to neurological signs ('control')

**Outcome:** 1 Death

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment</th>
<th>Control</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Fixed 95% CI</td>
<td></td>
<td>M-H, Fixed 95% CI</td>
</tr>
<tr>
<td>Smith 1986</td>
<td>14/37</td>
<td>17/40</td>
<td>0.83 [ 0.47, 1.46 ]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Subtotal (95% CI)

Total events: 13 (Treatment), 17 (Control)

Heterogeneity: not applicable

Test for overall effect: Z = 0.0 (P < 0.00001)

Test for subgroup differences: Not applicable

### Analysis 1.2. Comparison 1 ICP-directed mannitol ('treatment') compared to mannitol according to neurological signs ('control'), Outcome 2 Death or severe disability.

**Review:** Mannitol for acute traumatic brain injury

**Comparison:** 1 ICP-directed mannitol ('treatment') compared to mannitol according to neurological signs ('control')

**Outcome:** 2 Death or severe disability

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment</th>
<th>Control</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Fixed 95% CI</td>
<td></td>
<td>M-H, Fixed 95% CI</td>
</tr>
<tr>
<td>Smith 1986</td>
<td>17/37</td>
<td>21/40</td>
<td>0.88 [ 0.55, 1.38 ]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Subtotal (95% CI)

Total events: 17 (Treatment), 21 (Control)

Heterogeneity: not applicable

Test for overall effect: Z = 0.0 (P < 0.00001)

Test for subgroup differences: Not applicable
Analysis 2.1. Comparison 2 Mannitol versus pentobarbital, Outcome 1 Death.

Review: Mannitol for acute traumatic brain injury

Comparison: 2 Mannitol versus pentobarbital

Outcome: 1 Death

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment n/N</th>
<th>Control n/N</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schwartz 1984</td>
<td>15/31</td>
<td>16/28</td>
<td>0.85 [ 0.52, 1.38 ]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Subtotal (95% CI)

Total events: 15 (Treatment), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable

Analysis 3.1. Comparison 3 Mannitol versus hypertonic saline, Outcome 1 Death.

Review: Mannitol for acute traumatic brain injury

Comparison: 3 Mannitol versus hypertonic saline

Outcome: 1 Death

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment n/N</th>
<th>Control n/N</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vialet 2003</td>
<td>5/10</td>
<td>4/10</td>
<td>1.25 [ 0.47, 3.33 ]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Subtotal (95% CI)

Total events: 5 (Treatment), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
Analysis 4.1. Comparison 4 Mannitol versus placebo, Outcome 1 Death.

Review: Mannitol for acute traumatic brain injury

Comparison: 4 Mannitol versus placebo

Outcome: 1 Death

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment n/N</th>
<th>Control n/N</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sayre 1996</td>
<td>5/20</td>
<td>3/21</td>
<td>1.75 [ 0.48, 6.38 ]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]

Total events: 5 (Treatment), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable

APPENDICES

Appendix 1. Search strategies

Cochrane Injuries Group's Specialised Register
(mannitol or Mannit or Mannite or Osmosal or Osmosteril or Resectisol or Aridol or Bronchitol or bromine or mitobronitol or dibromomannitol or myelobromol or nsc-94* or osmitrol or osmo fundin or "(l)-mannitol" or “Dextro Mannitol” or D-Mannitol or (diuretic* and osmotic*)) AND (“intracranial pressure” OR “intracranial hypotension” OR “intracranial hypertension” or head* or brain*)

CENTRAL (The Cochrane Library)
#1MeSH descriptor Craniocerebral Trauma explode all trees
#2MeSH descriptor Cerebrovascular Trauma explode all trees
#3MeSH descriptor Brain Edema explode all trees
#4(brain or cerebral or intracranial) next (oedema or edema or swell*)
#5MeSH descriptor Glasgow Coma Scale explode all trees
#6MeSH descriptor Glasgow Outcome Scale explode all trees
#7MeSH descriptor Unconsciousness explode all trees
#8glasgow next (coma or outcome) next (score or scale)
#9(Unconscious* or coma* or concuss* or ‘persistent vegetative state’) near5 (injur* or trauma* or damag* or wound* or fracture*)
#10”Rancho Los Amigos Scale”
#11(head or cran* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) near3 (injur* or trauma* or damag* or wound* or fracture* or contusion*)
#12Diffuse next axonal next injur*
#13(head or cran* or cerebr* or brain* or intra-cran* or inter-cran*) near3 (haematoma* or hematoma* or haemorrhag* or hemorrhag* or bleed* or pressure)
Mannitol for acute traumatic brain injury (Review)
4.1 or 2 or 3
5.exp Brain Injury/
6.exp Brain Edema/
7.exp Glasgow Coma Scale/
8.exp Glasgow Outcome Scale/
9.exp Rancho Los Amigos Scale/
10.exp Unconsciousness/
11.(brain or cerebral or intracranial) adj5 (oedema or edema or swell*).ab,ti.
12.(head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) adj5 (injur* or trauma* or damag* or wound* or fracture* or contusion*).ab,ti.
13.(Glasgow adj (coma or outcome) adj (scale* or score*)).ab,ti.
15.(unconscious* or coma* or concuss* or ’persistent vegetative state’) adj3 (injur* or trauma* or damag* or wound* or fracture*).ti,ab.
17.(head or crani* or cerebr* or brain* or intra-cran* or inter-cran*) adj3 (haematoma* or hematoma* or haemorrhag* or hemorrhag* or bleed* or pressure)).ab,ti.
18.or/5-17
19.exp Randomized Controlled Trial/
20.exp controlled clinical trial/
22.placebo.ab.
23.*Clinical Trial/
24.randomly.ab.
25.trial.ti.
26.19 or 20 or 21 or 22 or 23 or 24 or 25
27.exp animal/ not (exp human/ and exp animal/)
28.26 not 27
29.28 and 18
30.4 and 29

ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) & Conference Proceedings Citation Index- Science (CPCI-S)
1.Topic=(mannitol or Mannit or Mannite or Osmosal or Osmosteril or Resectisol or Aridosil or Bronchitol or bromine or mitobronitol or dibromomannitol or myelobromol) OR Topic=(nsc-94* or osmitrol or osmofundin or ”(l)-mannitol” or ”Dextro Mannitol” or D-Mannitol or (diuretic* and osmotic*))
2.Topic=(intracranial pressure OR intracranial hypotension OR intracranial hypertension OR head OR brain)
3.TS=(clinical OR control* OR placebo OR random OR randomised OR randomized OR randomly OR random order OR random sequence OR random allocation OR randomly allocated OR at random) SAME TS=(trial* or group* or study or studies or placebo or controlled)
4.1 and 2 and 3

PubMed
1.(Mannitol OR Mannit OR Mannite OR Osmosal OR Osmosteril OR Resectisol OR Aridosil OR Bronchitol OR bromine OR Mitobronitol OR Dipromannitol OR Myelobromol OR Nsc-94* OR Osmitrol OR Osmofundin OR ”(l)-mannitol” OR ”Dextro Mannitol” OR D-Mannitol OR (diuretic* and osmotic*))
2.(”intracranial pressure” OR ”intracranial hypotension” OR ”intracranial hypertension” OR head OR brain)
3.(randomized controlled trial[pt] OR controlled clinical trial[pt]) OR (randomized OR randomised OR randomly OR placebo[tiab]) OR (trial[ti]) OR (“Clinical Trials as Topic”[MeSH Major Topic]) NOT (“Animals”[Mesh]) NOT (“Humans”[Mesh] AND “Animals”[Mesh]))
4.#1 AND #2 AND #3
FEEDBACK

Mannitol for acute traumatic brain injury

Summary

A. The search strategy would be clearer if the reviewer specified what additional search terms were used within the Injuries Group database to identify relevant articles (e.g., mannitol And acute brain injury). Also, the report does not specify whether any other databases, such as Medline or Embase, were searched, and if so, what search terms were used. The search should specify the total number of reports that were identified by the search strategy.

B. Would it be correct to interpret the review as demonstrating that there is no good evidence (i.e. no RCT’s comparing mannitol to placebo or alternate therapies) to support our current mannitol use post-head injury? Presumably current use of mannitol by clinicians is based primarily on the pharmacological activities of mannitol, observational human studies, and animal evidence supporting its potential benefit.

Reply

A. We did not use any additional search terms in the Injuries Group database apart from 'mannitol'. No other databases, such as EMBASE, were searched separately (these searches were already included in the Injuries Group database).

B. Yes - the review concludes that there is a lack of evidence for effectiveness, which is not the same as saying there is evidence of a lack of effectiveness.

Contributors

Dr Michael Bullard

WHAT’S NEW

Last assessed as up-to-date: 20 April 2009.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 August 2013</td>
<td>Amended</td>
<td>Copy edits made to the text.</td>
</tr>
</tbody>
</table>

HISTORY

Protocol first published: Issue 1, 1998

Review first published: Issue 1, 1998

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 April 2009</td>
<td>New search has been performed</td>
<td>The search has been updated to April 2009.</td>
</tr>
<tr>
<td>20 April 2009</td>
<td>New citation required but conclusions have not</td>
<td>The search has been updated to April 2009. No new trials were identified.</td>
</tr>
<tr>
<td></td>
<td>changed</td>
<td>The conclusions remain the same.</td>
</tr>
</tbody>
</table>
In response to concerns raised about the integrity of the data from the trials by Cruz et al, the Cochrane Injuries Group undertook an investigation in which attempts were made to find out where the patients were recruited and to access the original trial data for external validation. Despite considerable efforts the Group is unable to provide any reassurance about the integrity of trial data and for this reason the trials in question have been removed from the review.

**Contributions of Authors**

AW ran the searches, screened the citations for eligibility, extracted data, entered data into RevMan and wrote the updated review.

AM screened the citations for eligibility, entered data into RevMan and helped write the updated review.

IR screened citations, extracted data, helped to write the original review.

GS designed and ran the searches, screened the citations for eligibility, contacted authors, extracted data, entered data into RevMan and wrote up the original review.

**Declarations of Interest**

None known.

**Sources of Support**

**Internal sources**

- Department of Emergency Medicine, St. Vincent's University Hospital, Dublin 4, Ireland.

**External sources**

- NHS R&D Programme: mother and child health, UK.
- The Higher Specialist Training Scheme in Emergency Medicine, Ireland.
INDEX TERMS

Medical Subject Headings (MeSH)
Acute Disease; Brain Injuries [complications; *drug therapy; mortality]; Diuretics, Osmotic [*administration & dosage; adverse effects]; Intracranial Hypertension [etiology; *prevention & control]; Intracranial Pressure [drug effects]; Mannitol [*administration & dosage; adverse effects]; Pentobarbital [administration & dosage]; Randomized Controlled Trials as Topic; Saline Solution, Hypertonic [administration & dosage]

MeSH check words
Humans